IART as reported
Integra LifeSciences Holdings Corporation reported $1.64B of revenue over the trailing twelve months, +1.2% on the year before. 11 reported series are charted on this page, each one as filed.
$1.64B
Revenue, trailing twelve months · to Q1 2026 · +1.2% against the twelve months before
- Net Income
- −$496M
Net Income · +1612% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $4.1M
Free Cash Flow · −126% year on year · trailing twelve months to Q1 2026
- Op Margin
- −28%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.64B | +1.2% | Q1 2026 |
| Net Income | −$496M | +1612% | Q1 2026 |
| EPS | −$6.46 | +1600% | Q1 2026 |
| Gross Margin | 52% | n/a | Q1 2026 |
| Op Margin | −28% | n/a | Q1 2026 |
| Net Margin | −30% | n/a | Q1 2026 |
| ROE | −48% | n/a | Q1 2026 |
| ROA | −14% | n/a | Q1 2026 |
| ROIC | −25% | n/a | Q1 2026 |
| Free Cash Flow | $4.1M | −126% | Q1 2026 |
| P/E | 63.9 | n/a | Q2 2024 · 7 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Integra LifeSciences Holdings Corporation (IART) - Revenue & ProfitRevenue & ProfitIntegra LifeSciences Holdings Corporation (IART)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com